Maven Renovar VCT12 May 2025 09:36
Taken from Mavens Annual Financial Report published on 16th April 25, reporting on Year End January 25.
"Feedback (1.0m investment), a provider of a communication and collaboration software platform to the NHS called Bleepa, which connects care settings with diagnostic and other relevant data to drive better, faster, and safer clinical decisions. Bleepa provides one of very few routes to allow GP patient records to be brought together with hospital patient records in a seamless fashion, allowing each medical practitioner involved with a patient to collaborate. From its current user base, Bleepa has demonstrated that 90% of referrals of patients from GPs to specialists do not require an outpatient appointment, but rather in most cases the specialist only needs to see all of the clinical information already gathered to give an opinion in 5-6 minutes, whereas a typical outpatient appointment takes 30 minutes, much of which is taken up gathering information already in the clinical records. As collaboration between doctors is so poorly provided for currently, it is estimated that over 90% of doctors use WhatsApp as a messaging platform to do so, in contravention of data protection regulations. We are acutely aware that the NHS is a poor buyer of technology, even when the benefits that a new product promises to bring to them are huge. However, we saw in Bleepa the potential to provide such a key piece of technology to assist with the Government's stated ambition to bring down patient waiting lists through efficiency gains, that we chose to support the company with the next phase of its development, during which we expect to see some significant adoption of Bleepa. Because of the depressed state of AIM, we were able to buy an 11.9% stake in the business fully funded for scale up, for our 1m investment. Gareth Blades has become a Board Observer for Feedback."
https://www.theaic.co.uk/companydata/maven-renovar-vct/announcements/8833424
Sign In
Follow the stocks
